Bottiroli, Maurizio
Calini, Angelo
Pinciroli, Riccardo
Mueller, Ariel
Siragusa, Antonio
Anelli, Carlo
Urman, Richard D.
Nozari, Ala
Berra, Lorenzo
Mondino, Michele
Fumagalli, Roberto
Article History
Received: 3 March 2021
Accepted: 6 May 2021
First Online: 20 May 2021
Declarations
:
: The present study received approval by the Institutional Review Board of the coordinating institution (Massachusetts General Hospital, Boston, MA, USA, Protocol #2020P000760) with a waiver of informed consent. Patients included in this study were all admitted to Niguarda Hospital, Milan, Italy (Approval No.183–15042020). The study protocol is performed in accordance with the STROBE checklist for cohort studies.
: Not applicable.
: AM reports receiving statistical consulting fees from the University of Chicago. RDU reports unrelated fees or research funding from Merck, Covidien/Medtronic, AcelRx, Acacia Pharma, Takeda, and federal funding by the NIH NIH/NIDA - 1R34DA048268-01A1, AHRQ R01 HS025718-01A1, NSF Award #1838796.LB receives salary support from K23 HL128882/NHLBI NIH as principal investigator for his work on hemolysis and nitric oxide. LB receives technologies and devices from iNO Therapeutics LLC, Praxair Inc., Masimo Corp. LB receives a grant from iNO Therapeutics LLC. The other authors declare no competing interests.